68120-44-5

Usage

Uses

Used in Pharmaceutical Industry:
1-BROMO-4-BROMOMETHYL-2-CHLORO-BENZENE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 1-BROMO-4-BROMOMETHYL-2-CHLORO-BENZENE serves as a building block for the production of agrochemicals, such as pesticides and herbicides, which are essential for crop protection and increased agricultural productivity.
Used in Dye Production:
1-BROMO-4-BROMOMETHYL-2-CHLORO-BENZENE is utilized as a starting material in the synthesis of dyes, which are used in various applications such as textiles, plastics, and printing inks.
Used in Polymer Industry:
This chemical compound is also used in the polymer industry as a monomer or a building block for the production of polymers with specific properties, such as flame retardancy or UV resistance.
Used in Specialty Chemicals Production:
1-BROMO-4-BROMOMETHYL-2-CHLORO-BENZENE is employed in the synthesis of specialty chemicals, which have unique applications in various industries, including coatings, adhesives, and sealants.
However, it is crucial to handle 1-BROMO-4-BROMOMETHYL-2-CHLORO-BENZENE with caution due to its toxic nature. It can cause skin and eye irritation, as well as respiratory and digestive tract issues if inhaled or ingested. Additionally, it is harmful to aquatic organisms and may cause long-term adverse effects in the environment. Proper safety measures and disposal methods should be followed to minimize its impact on human health and the environment.

Upstream product

• 6627-51-6 1-bromo-2-chloro-4-methylbenzene 
• 120077-68-1 (4-bromo-3-chlorophenyl)methanol 
• 120077-67-0 4-bromo-3-chlorobenzoic acid ethyl ester 
• 25118-59-6 4-bromo-3-chlorobenzoic acid 

Downstream Products

• 72702-90-0 ethyl 2-(3-chloro-4-bromobenzyl)-1,2-dihydro-1-oxophthalazin-4-ylacetate 
• 1092069-95-8 C₁₁H₁₃BrClN 
• 1092069-97-0 C₁₃H₁₆ClNO₃ 
• 1092069-96-9 C₁₂H₁₄ClNO 
• 1259023-29-4 2-(4-bromo-3-chlorophenyl)acetonitrile 

Relevant academic research and scientific papers

MLKL INHIBITORS

Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds displaying unexpected high CNS penetration. Increased MDCK efflux was utilized to identify compounds such as 33 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated. Differential activity was observed in GPR120 null and wild-type mice indicating that this effect operates through a mechanism involving GPR120 agonism.

Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors

Neuronal nitric oxide synthase (nNOS) is a target for development of antineurodegenerative agents. Most nNOS inhibitors mimic l-arginine and have poor bioavailability. 2-Aminoquinolines showed promise as bioavailable nNOS inhibitors but suffered from low

AMIDE COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS

The present invention is directed to amide compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment or prevention of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, fibrotic, and low bone mass diseases, as well as cancer.

HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The com-pounds can be used in methods of treating proliferative dis-eases and disorders such as cancer

CHEMICAL COMPOUNDS 785

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.

Thiazolyl-Dihydro-Indazole

The present invention encompasses compounds of general formula (1) wherein R1 to R6 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use th

Imidazole derivatives

Imidazole derivatives of the formula: STR1 wherein R1 represents hydrogen, or an alkyl group containing from 1 to 10 carbon atoms or an alkenyl or alkynyl group containing from 2 to 10 carbon atoms, and R2, R3 and R4